L-838,417

L-838,417 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.L-838,417 (other names: L-838417) is an anxiolytic drug developed by Merck, Sharp and Dohme, classified as a non-benzodiazepine, but with similar effects. L-838,417 is a subtype-selective GABAA modulator, acting as a partial agonist at alpha2, alpha3 and alpha5 subtypes and an antagonist at the alpha1 subtype. L-838,417 displays anxiolytic effects in vivo and is used as a tool compound to study roles of GABAA subunits.

Pharmacology
L-838,417 acts on GABA receptors with an allosteric modulator and acts as a partial agonist in α2, α3, α5 and acts as a negative allosteric modulator in α1 and with little affinity for α4 or α6.This explains the anxiolytic effects, and can also cause a sedative effect, however, in animal studies, sedative effects were not detected even at high doses.
The synthesis of this substance was described in 2005 in the Journal of Medicinal Chemistry.
It has also been found in animal studies that when exposed to the drug L-838,417, potassium chloride cotranspoter 2 (KCC2) stabilizes on the membranes of neurons, which leads to an analgesic effect.

Technical Information:

Product Name: L-838,417
Other Name(s): L-838417
IUPAC Name: 7-tert-butyl-3-(2,5-difluorophenyl)-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine
CAS: 286456-42-6
Molar Mass: 399.4 g/mol
Molecular Formula: C19H19F2N7O
InChi Code: InChI=1S/C19H19F2N7O/c1-19(2,3)13-8-15-24-25-17(12-7-11(20)5-6-14(12)21)28(15)26-18(13)29-9-16-22-10-23-27(16)4/h5-8,10H,9H2,1-4H3
InChIKey: BQDUNOMMYOKHEP-UHFFFAOYSA-N
Canonical SMILES: CC(C)(C)C1=CC2=NN=C(N2N=C1OCC3=NC=NN3C)C4=C(C=CC(=C4)F)F
Formulation: A crystalline solid